Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT06992284
Enrolling by invitation Observational

A Prognostic Study for Patients With Cardiovascular Disease in Niigata

NCT06992284 · tracked via the Priya Life Science Japan tracker
Sponsor
Niigata University Medical & Dental Hospital
Phase
Observational
Started
2025-05-12
Last updated
2025-05-28

Condition(s) studied

Cardiovascular DiseasesHeart Failure

Study summary

The goal of this observational study is to investigate the prognosis of cardiovascular disease in Niigata Prefecture.

Specifically, it aims to clarify the current status of medical treatment for cardiovascular disease patients in regional cities in Japan, where the population is aging.

With patient consent, the study will track long-term medical treatment progress using health insurance claim data recorded in Japan's unique social security system.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Individuals aged 18 or older at the time of enrollment (regardless of gender). * Individuals who have been hospitalized in the cardiology department of a participating medical institution. * Individuals covered by Japan's National Health Insurance (NHI) or the Late-stage Elderly Medical Care System, which provide health coverage for self-employed individuals, retirees, and the elderly. Exclusion Criteria: * Individuals who are unable to obtain consent from themselves or their legally authorized representatives.

Primary outcome measure(s)

  • The rate of deterioration in care dependency levels as defined by Japan's Long-Term Care Insurance system — through study completion, an average of 1 year
    through study completion, an average of 1 year

Trial sites (1)

FacilityCityRegionStatus
Niigata University Niigata Niigata

More Niigata University Medical & Dental Hospital trials in Japan

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma Active, not recruiting

Other trials for the same condition

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific Recruiting
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices Active, not recruiting
Feedback Using behaviOral econOmic Theories on STEP countS in Cardiovascular Disease Patients Active, not recruiting
A Study of LY3971297 in Participants With Heart Failure Recruiting
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06992284 on ClinicalTrials.gov ↗ ← All trials in Japan